Cyto-Facto Inc. provides services for manufacturing, development, and quality control testing of gene and cell preparations

Cyto-Facto Inc, a CMO/CDMO Company specialized in gene and cell therapies, signed a Memorandum of Understanding (MOU) with Hoa Lam Shangri-La Healthcare Limited Liability Company on December 17, 2024. The agreement aims to promote technical education and business development in the field of gene and cell therapies.

The signing ceremony was held at Gia An 115 Hospital, Gia An 115 Hospital in Ho Chi Minh City. The exchange of signatures was conducted by Ms. Tran Thi Lam, Founding Chairwoman of Hoa Lam Group, and Shin Kawamata, CEO of Cyto-Facto. The event was also attended by Dr. Nguyen Ngo Quang, Director General and Dr. Hoang Hoa Son, Deputy Head of Science and Technology Management from Administration of Science, Technology and Training, Ministry of Health, Vietnam.

About Hoa Lam Group
Hoa Lam Group is a diversified business conglomerate in Vietnam, operating across industries such as manufacturing, finance, real estate, education, and healthcare. In the healthcare sector, the company operates the International Hi-Tech Healthcare Park (IHHP) through its subsidiary, Hoa Lam Shangri-La Healthcare. This park provides the cutting-edge medical technology and services that meet international standards. The company also operates the International Hospital and Gia An 115 Hospital. These hospitals provide comprehensive support for acute care, medical treatment, and rehabilitation. The group is also pursuing expansion plans across Vietnam to meet expanding healthcare demands in Southeast Asia.

About the Partnership
Through this agreement, Cyto-Facto and Hoa Lam Shangri-La Healthcare will collaborate in the business development of cell, stem cell, and gene therapy. Cyto-Facto will provide training, consulting, and technology transfer for the manufacturing of cells and stem cells according to Japanese quality standards. We will also provide consulting for the production of gene-cell products using Hoa Lam Shangri La Healthcare's facilities.

Cyto-Facto is committed to building a Southeast Asian network for gene and cell therapy through this partnership, aiming to establish itself as a regional hub for the manufacturing of gene and cell therapies in the Asia-Pacific region.

For further inquiries,please contact our communications team at info@cytofacto.com.

Left:Commemorative photo with all participants of the signing ceremony
Right:From left to right,Dr.Hoang Hoa Son(Deputy Head of Science and Technology Management,Administration of Science,Technology and Training of Ministry of Health,Vietnam),Ms.Tran Thi Lam(Founding Chairwoman of Hoa Lam Group),Dr.Nguyen Ngo Quang(Director General,Administration of Science,Technology and Training of Ministry of Health,Vietnam),and Shin Kawamata(CEO,Cyto-Facto Inc.)